There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Portola Pharma (PTLA) and Sarepta Therapeutics (SRPT) with bullish sentiments.
Portola Pharma (PTLA)
Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Portola Pharma yesterday and set a price target of $45. The company’s shares closed yesterday at $27.14.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 3.6% and a 46.4% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Phasebio Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Portola Pharma with a $43.50 average price target.
See today’s analyst top recommended stocks >>
Sarepta Therapeutics (SRPT)
In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on Sarepta Therapeutics, with a price target of $213. The company’s shares closed yesterday at $142.26.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 22.3% and a 48.1% success rate. Baral covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.
Currently, the analyst consensus on Sarepta Therapeutics is a Strong Buy with an average price target of $214.70.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
